

Leveraging 4 Key Drivers in a \$6.36 Billion PFS Market at 10th Annual Pre-Filled Syringes Show

SMi Group returns to Central London next January with its 10th annual event, Pre-Filled Syringes Europe 2018

LONDON, ENGLAND, UNITED KINGDOM, October 26, 2017 /EINPresswire.com/ -- A recent report has predicted the Global Prefilled Syringes Market to exceed more than US\$ 6.36 Billion by 2022 at a CAGR of 10.1%. In light of this, SMi Group will return to Central London next January with its 10th annual event, <u>Pre-Filled Syringes Europe 2018</u>, to leverage key drivers affecting a rapidly booming market. *Source: <u>http://bit.ly/2gpR3Pd</u>

1. Simplicity and ease of use: Pre-Filled Syringes reduce the number of steps required for drug administration whilst improving safety by reducing the potential for drug contamination, needlestick injuries and dosing errors. What makes injection safe? Attendees PFS Europe 2018 will explore common user problems, statistics and legislation



for safety systems and learn more on why human-centred design matters.

2. The rising levels of chronic diseases have led to a significant increase in the use of injectable drugs. Attendees will discuss technical challenges in meeting specialised drug product requirements. A

"

This is the kind of valueadded that you can only get when joining conferences. " West Pharmaceutical Services notable panel of speakers will provide informed guidance on primary packaging material selection, drug product stability, manufacturing, large volume injectables and device safety to meet specialised demands in parenteral drug products.

3. Pharmaceutical companies can differentiate their brands with drugs sold in pre-filled syringes.

With the rise of biosimilars, innovations in pre-filled syringes can facilitate meaningful differentiation of products. The

agenda for Pre-Filled Syringes 2018 will provide strategic direction presented by big pharma.

4. Improvements in technology and manufacturing to lower levels of extractables and leachables and to cater for biologics and more sensitive drugs will encourage drug companies to switch to pre-fills. Attendees will draw from case studies on leachable assessment in prefilled syringes and learn about the different relationship between extractables, simulated leachables and leachables in PFS.

SMi's 10th annual 2018 <u>Pre-Filled Syringes Europe</u> conference and exhibition will take place on 17th & 18th Jan at the Copthorne Tara Hotel, Kensington, London UK.

Further information including a detailed agenda and full speaker line-up is available at www.pre-filled-

syringes.com

--- END ---

Contact Information:

For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk For all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smionline.co.uk

Sponsors of Pre-Filled Syringes Europe 2018 include: 3P Innovation, Früh Verpackungstechnik AG, Intertek (Schweiz) AG, Mitsubishi Gas Chemical, Nemera, Nipro PharmaPackaging, Owen Mumford, Panasonic Healthcare, Terumo Pharmaceutical Solutions, West Pharmaceutical Services, Worrell, Inc. & Zeon

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri SMi Group 2078276000 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2017 IPD Group, Inc. All Right Reserved.